CDRD, Canada’s national drug development and commercialization centre, is pleased to share that “ZW49” by Zymeworks is the first product candidate selected for clinical development utilizing the ZymeLink™ antibody-drug conjugate (ADC) platform, acquired as part of the Company’s 2016 acquisition of Kairos Therapeutics.
ZW49 was developed by leveraging ZymeLink in combination with Zymeworks’ flagship Azymetric™ bispecific platform. The Company expects to file an Investigational New Drug (IND) application this year in order to begin clinical trials with ZW49 for patients with HER2-expressing cancers.
CDRD spin-off company Kairos Therapeutics was launched in 2013 based on novel toxin and linker inventions discovered, developed and validated at CDRD. In early 2016, Kairos was acquired by BC-based Zymeworks – a transaction that resulted in the creation of Canada’s largest biologics company and significant potential financial returns for CDRD. See more info about Kairos here: cdrd.ca/outcomes-impact/spin-off-companies/
See full information posted in Zymeworks press release at: ir.zymeworks.com/news-releases/2018/03-14-2018-200635500
For additional information, please contact:
Senior Manager, Communications
CDRD (The Centre for Drug Research & Development)